208 Identification of Trichomonas vaginalis 5-nitroimidazole resistance targets to inform future drug development

OBJECTIVES/GOALS: 5-nitroimidazoles are the only FDA-approved medications for T. vaginalis treatment. Resistance has been observed in 5-10% of cases, but may be rising. We aimed to delineate mechanisms of resistance in isolates of T. vaginalis using transcriptome profiling of resistant and sensitive...

Descripción completa

Detalles Bibliográficos
Autores principales: Graves, Keonte, Sharma, Jyoti, Reily, Colin, Tiwari, Hemant, Srinivasasainagendra, Vinodh, Secor, W. Evan, Novak, Jan, Muzny, Christina A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2022
Materias:
Education
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9209190/
http://dx.doi.org/10.1017/cts.2022.110

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9209190/
http://dx.doi.org/10.1017/cts.2022.110

Ejemplares similares